The PARIS score allows combined stratification of ischemic and hemorrhagic risk in patients with ischemic heart disease treated with coronary stenting and dual antiplatelet therapy (DAPT). Its usefulness in patients with acute coronary syndrome (ACS) treated with ticagrelor or prasugrel is unknown. We investigated this issue in an international registry.
Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome
D'Ascenzo, Fabrizio;Cerrato, Enrico;Quadri, Giorgio;Montabone, Andrea;Gili, Sebastiano;Autelli, Michele;Grosso, Alberto;Gaita, Fiorenzo;
2018-01-01
Abstract
The PARIS score allows combined stratification of ischemic and hemorrhagic risk in patients with ischemic heart disease treated with coronary stenting and dual antiplatelet therapy (DAPT). Its usefulness in patients with acute coronary syndrome (ACS) treated with ticagrelor or prasugrel is unknown. We investigated this issue in an international registry.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
paris.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
427.12 kB
Formato
Adobe PDF
|
427.12 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
